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ABSTRACT
Background. Eculizumab, a terminal complement inhibitor, is approved for atypical haemolytic uraemic syndrome (aHUS)
to inhibit complement-mediated thrombotic microangiopathy (TMA).
Methods. In five parent studies, eculizumab effectively prevented TMA and improved renal and haematologic outcomes in
patients with aHUS; therefore, these patients could enrol in this long-term, prospective, observational and multicentre
study. The primary endpoint was the TMA manifestation rate off and on eculizumab post-parent study. Post hoc analyses
evaluated rates during labelled versus non-labelled dosing regimens, and in those with versus without identified
complement abnormalities. Serious targeted treatment-emergent adverse events (TEAEs) were evaluated.
Results. Of 87 patients in the current study, 39 and 76 had off- and on-treatment periods, respectively; 17 (44%) with off periods
reinitiated eculizumab. TMA manifestation rate per 100 patient-years was 19.9 off and 7.3 on treatment [hazard ratio (HR), 4.7;
P¼0.0008]; rates were highest off treatment and lowest during labelled regimens. TMA manifestations with hospitalizations/
serious AEs occurred more frequently off versus on treatment. TMA rates were higher among patients with identified
complement abnormalities (HR, 4.5; P¼0.0082). Serious targeted TEAEs occurred at similar rates off and on treatment.
Conclusions. As expected, patients with aHUS have increased risk of TMA manifestations after discontinuation of
eculizumab or in the setting of non-labelled eculizumab dosing. Collectively, results show that maintaining eculizumab
treatment minimizes risk of TMA, particularly in patients with identified complement abnormalities. Future studies are
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needed to further characterize TMA and longer term outcomes on labelled or non-labelled eculizumab regimens and after
discontinuation of treatment.
Keywords: atypical haemolytic uraemic syndrome, complement, discontinuation, eculizumab, observational study,
thrombotic microangiopathy
INTRODUCTION
Atypical haemolytic uraemic syndrome (aHUS) is a rare, genetic,
potentially life-threatening disease predominantly caused by
uncontrolled activation of the alternative complement pathway
[1–3]. Abnormalities in complement genes or autoantibodies to
complement proteins are identified in50–70% of patients
[2, 3]. Complement dysregulation leads to persistent cleavage of
C5 to the prothrombotic, pro-inflammatory anaphylatoxin C5a
and to C5b, which initiates formation of the prothrombotic and
cytolytic C5b-9 and ultimately causes injury, activation and
lysis of endothelial cells, leucocytes and platelets [1, 4]. The
resultant thrombotic microangiopathy (TMA) is typically
characterized by microangiopathic haemolytic anaemia, throm-
bocytopaenia and acute renal failure, and frequently includes
extrarenal complications [2, 3].
Patients who remain untreated are at lifelong risk of renal
impairment or failure, organ dysfunction and premature death
[2, 3]. Eculizumab (SolirisVR , Alexion Pharmaceuticals, Inc., New
Haven, CT, USA), a humanized monoclonal antibody that inhib-
its C5a, C5b and C5b-9 formation by binding to C5, is the first
and only approved treatment for patients with aHUS [5, 6]. The
efficacy and safety of eculizumab have been demonstrated in
four prospective, multicentre clinical studies [7–10] and a retro-
spective study [11].
Current regulatory guidance notes potential risk of TMA fol-
lowing discontinuation of eculizumab [5, 6]. Additional evidence
for TMA manifestations occurring after discontinuation is lim-
ited to case studies [12–25], two retrospective studies [26, 27]
and a small prospective observational study [28, 29]. Together,
TMA manifestations were documented in 26/82 patients (32%)
who discontinued eculizumab [12–29]. An analysis [30] from the
eculizumab clinical trial programme determined that severe
TMA manifestations occurred in 12/61 patients (20%) who chose
to discontinue treatment.
This is the single largest prospective, observational study of
the consequences following eculizumab discontinuation in
aHUS. In an interim analysis, TMA manifestation rates off and
on eculizumab in patients with aHUS were evaluated. Post hoc
analyses based on a revised, more stringent definition of TMA,
during labelled versus non-labelled regimens and by comple-
ment abnormality status, also were conducted. In addition, the
safety of long-term eculizumab is reported.
MATERIALS ANDMETHODS
Study design and patients
This is a long-term, prospective, observational and multicentre
study (NCT01522170) of patients with aHUS who were treated
with eculizumab in any of five previous clinical studies (parent
studies): four prospective studies (NCT00844545/NCT00844844
and NCT00838513/NCT00844428 [7, 8], NCT01193348 [9],
NCT01194973 [10]) and one retrospective study (NCT01770951
[11]). Patients who participated in a parent study were eligible
for the current study, regardless of whether they completed or
discontinued from the parent study or were on eculizumab at the
time of enrolment. Patients could withdraw from the current study
at any time. The protocol was approved by an institutional review
board or independent ethics committee at each participating cen-
tre and the study was conducted in accordance with International
Council for Harmonisation Guidelines and the Declaration of
Helsinki. All patients and/or parents/guardians provided written
informed consent before entry into the current study.
The current study consequently includes both prospective
and retrospective data collection. Retrospective data were
obtained from the date each patient ended participation in the
parent study until the date of signed informed consent for the
current study. All patients who received at least one infusion of
eculizumab during the parent study and had signed consent
forms for the current study were included in the analysis.
Identification of complement abnormalities occurred during the
parent studies and included analysis of complement factor I
(CFI), complement factor B (CFB), complement factor H (CFH),
membrane cofactor protein (MCP) and C3 mutations, comple-
ment factor H-related proteins 1-3 (CFHR1-3) deletions/polymor-
phisms and CFH autoantibodies [7, 9–11]. Patients received
meningococcal vaccination in the parent studies [7, 9, 10] and
were revaccinated according to country guidelines. The cut-off
date for this interim analysis was 28 March 2015.
TMA manifestations were neither defined nor collected uni-
formly in the parent studies; thus, this analysis includes out-
comes reported in this ongoing observational study only (i.e.
beginning at the end of the parent study). Data were collected
four times annually in both the retrospective and prospective
portions of the current study.
Treatment
After completion of the parent study and entry into the current
study, the labelled dosing regimen of eculizumab was defined
as that specified in the prescribing information approved by
regulatory authorities [5, 6], and other dosing schedules (i.e. de-
creased or increased dosages, shortened or extended dosing
intervals) were permitted and classified as non-labelled regi-
mens. In this study, the first on-treatment period was defined
as: from the date of the first infusion in the current study (i.e.
beginning at the end of the parent study) through 3 weeks after
the last infusion of eculizumab, or until the patient discontin-
ued from the study, or data cut-off (whichever occurred first).
The first off-treatment period was defined as: from 3 weeks af-
ter the last infusion of eculizumab within the current study un-
til the patient restarted eculizumab therapy, discontinued from
the study or data cut-off (whichever occurred first). Subsequent
on- and off-treatment periods were defined similarly. Patient
groups were not mutually exclusive; individual patients could
be represented in both groups.
Endpoints
Primary endpoint was the rate of TMA manifestations (defined
in Table 1) in the current study off and on treatment. Post hoc
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analyses evaluated TMA manifestation rates off and on treat-
ment when TMA manifestations based on only a single labora-
tory value change were excluded; in patients receiving labelled
compared with non-labelled eculizumab regimens; and in
patients with and without identified complement abnormali-
ties. Safety endpoints included assessment of serious targeted
treatment-emergent adverse events (TEAEs; predefined as inci-
dence of serious infection, meningococcal infection, sepsis, re-
nal impairment or leucopaenia), as well as any serious AE (SAE).
Statistical methods
Time to first TMA manifestation was defined as time from the
start of the current study (i.e. end of the parent study) to first
TMA manifestation during the current study. Patients who did
not have a TMA manifestation were censored at data cut-off or
study discontinuation, whichever occurred first. Time to first
TMA manifestation was analysed using Cox proportional haz-
ards models with treatment status as a time-dependent explan-
atory variable and complement abnormality status as a
covariate. Hazard ratios (HRs) and P values were obtained for
comparisons off and on treatment and between identified and
no identified complement abnormality subgroups.
RESULTS
Patients and exposure
Overall, 130 patients were enrolled in the parent studies. By the
data cut-off for this analysis, 87 patients had enrolled in the cur-
rent study. Of these, 39 (45%) had off-treatment periods whereas
76 (87%) had on-treatment periods. Seventeen patients (44%)
with off-treatment periods reinitiated eculizumab; of these, 14
(82%) remained on therapy once they reinitiated (Figure 1). Age,
frequency of complement abnormalities and kidney transplant
status were not different between patients with ongoing eculi-
zumab therapy versus those who discontinued (Table 2).
Twenty-two patients (25%) had renal transplants, including
eight patients (21%) who discontinued eculizumab and 14 (29%)
on ongoing eculizumab. A median (range) of 11.0 (0.0–230.0)
plasma exchanges or plasma infusions were used by the overall
population before eculizumab initiation, including 7.0 (0.0–64.0)
in patients who discontinued eculizumab and 13.3 (0.0–230.0) in
patients who never discontinued eculizumab. Dialysis was re-
quired by 29/87 patients (33%) before parent study enrolment,
and use was more frequent in those who discontinued eculizu-
mab (39%) compared with those who never discontinued eculi-
zumab (29%). Including parent studies, patients had a total
median (range) of 45.9 (1.3–86.9) months of eculizumab expo-
sure. In the current study, median (range) follow-up was 20.1
(0.7–79.5) months off and 26.1 (0.7–64.2) months on treatment.
Compared with patients who continued on eculizumab,
those who discontinued had a shorter interval from initial aHUS
diagnosis, as well as the most recent pretreatment TMA mani-
festation, to first-ever eculizumab dose in the parent study.
Patients who discontinued also presented with lower estimated
glomerular filtration rates (eGFRs) and were more frequently di-
alysis dependent at initiation of eculizumab (Table 2).
Non-labelled eculizumab regimens were received by 33/87
patients (38%) during the current study. Of these, 11 always re-
ceived non-labelled doses and 22 had periods of labelled and
non-labelled regimens. Median (range) duration of therapy was
25.7 (0.5–60.4) months during labelled and 14.3 (0.4–64.3) months
during non-labelled regimens. Dosing higher than labelled
accounted for 0.4% of the total patient-years for non-labelled
regimens.
TMAmanifestations
When using the per-protocol definition (Table 1), 28 TMA
manifestations occurred. This included 14 TMA manifestations
in 11/39 patients (28%) off treatment and 14 TMA manifesta-
tions in 10/76 patients (13%) on treatment (Tables 3 and 4).
TMA manifestation rate per 100 patient-years was 19.9 off and
7.3 on treatment (63% lower; HR, 4.7; P¼ 0.0008; Table 5).
Table 1. Per-protocol definition of TMAmanifestations (any1 listed criteria)
Type/severity Criteria
Laboratory value
change onlya
The occurrence of a change in 1 laboratory valueb:
• Platelet count decrease 25% compared with baselinec and <LLN
• Increase in SCr or LDH level 25% compared with baselinec and >ULN
Clinical signs and
symptoms of TMAd
Clinical signs and symptoms of TMA considered definitely related to aHUS, including:
• Thrombosis
• Seizure
• Decreased renal function
• Proteinuria (new or worse compared with baseline and >1þ or >30 mg/dL)
• Haematuria (new or worse compared with baseline and >50 RBC/HPF)
• Increased haemolytic anaemia
• Biopsy-proven TMA
• Other (e.g. extrarenal TMA manifestations including confusion, cardiovascular abnormalities,
pericarditis, gastrointestinal symptoms and diarrhoea)
Interventiond The patient received PE/PI, dialysis, blood transfusions or renal transplant due to a TMA manifestation
aAs determined by changes in laboratory parameters with ongoing follow-up.
bMeasurements were required to be confirmed by a second measurement28 days apart with no interruption.
cBaseline was defined for each on period as the last laboratory value during the preceding off period, and for each off period as the last value during the preceding on
period.
dAs determined at the discretion of the investigator.
HPF, high-powered field; LDH, lactate dehydrogenase; LLN, lower limit of normal; PE/PI, plasma exchange/plasma infusion; RBC, red blood cells; SCr, serum creatinine;
ULN, upper limit of normal.
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Patients treated with non-labelled and labelled regimens had
TMA manifestation rates of 12.1 and 5.2 per 100 patient-years,
respectively (39% and 74% lower, respectively, versus off
treatment).
Characteristics of TMAmanifestations
TMA manifestations off treatment were more frequently associ-
ated with multiple laboratory criteria for TMA, clinical signs and
symptoms of TMA, interventions, SAEs and/or hospitalizations
(Tables 3 and 4). Eleven of 14 TMA manifestations (79%) in
patients off treatment included multiple laboratory TMA criteria
and/or an intervention, compared with 2/14 TMA manifesta-
tions (14%) on treatment. Patients required hospitalization dur-
ing 9/14 TMA manifestations (64%) off treatment and 3/14 TMA
manifestations (21%) on treatment.
TMAmanifestation rate excluding TMAs based on
single laboratory value changes
An abnormality in a single laboratory value may not be
considered as TMA clinically; therefore, a post hoc analysis was
performed to better reflect TMA evaluation in clinical practice.
TMA defined by a change from baseline in a single laboratory
value occurred in 3/14 TMA manifestations (21%) off treatment
and 12/14 TMA manifestations (86%) on treatment (Tables 3
and 4). When using this definition, 11 TMA manifestations
occurred in 8/39 patients (21%) off treatment and two TMA
manifestations occurred in 2/76 patients (3%) on treatment.
The TMA manifestation rate per 100 patient-years was 15.6 off
and 1.0 on treatment (94% decrease; HR, 16.8; P¼ 0.0010)
(Table 5).
TMAmanifestations by complement abnormality status
The majority of patients who reported TMA manifestations as
defined per protocol had complement abnormalities (Tables 3
and 4), particularly in those with CFH [10/17 (59%)] and CFI
mutations [4/17 (24%)]. Rates were higher for patients with iden-
tified complement abnormalities compared with no identified
complement abnormalities (HR, 4.5; P¼ 0.0082).
Safety
Overall, treatment with eculizumab was well tolerated. The oc-
currence of serious targeted TEAEs during the current study was
similar off and on treatment (Table 6). Two patients from the par-
ent retrospective study reported meningococcal infections during
the current study; both were determined to be probably related to
eculizumab. Both patients were treated and recovered while con-
tinuing eculizumab on schedule. Diagnoses/underlying condi-
tions associated with reported serious targeted TEAEs of renal
impairment that did not meet criteria for TMA included new kid-
ney transplant, renal graft rejection, multiorgan failure, dehydra-
tion, infection and interstitial tubulopathy. One adult patient,
who received non-labelled dosing during the current study,
FIGURE 1: Patient disposition.
4 | J. Menne et al.
Downloaded from https://academic.oup.com/ckj/advance-article-abstract/doi/10.1093/ckj/sfy035/4996707
by University of Newcastle user
on 25 May 2018
died due to severe intensive care complications and severe multi-
organ dysfunction after gastrointestinal haemorrhage, lithiasic
cholecystitis and severe sepsis, which were determined to be
unrelated to eculizumab.
DISCUSSION
Results from this interim analysis of a non-randomized, pro-
spective observational study demonstrate that rates of TMA
manifestations in patients with aHUS were 2.7-fold higher off
compared with on eculizumab (63% lower), despite longer
follow-up on treatment. TMA manifestation rates were lowest
during labelled dosing regimens (74% lower than off treatment),
higher during non-labelled regimens (39% lower than off treat-
ment) and highest off treatment.
The per-protocol definition of TMA manifestations was broad,
including changes in laboratory values, clinical signs and symp-
toms of TMA related to aHUS, and/or interventions related to
TMA. Thus, reported TMA per this definition represented varying
degrees of clinical deterioration. Importantly, there is no single,
agreed-upon definition of TMA based upon a single laboratory
value in clinical practice. TMA manifestations off treatment were
associated with multiple laboratory criteria, clinical sequelae (e.g.
renal impairment and acute renal failure), SAEs, hospitalizations
and/or required interventions (e.g. transfusion) in 13/14 cases
(93%). In contrast, TMA manifestations on treatment typically
comprised changes in single laboratory values with no clinical
signs/symptoms. Therefore, post hoc analyses were conducted to
provide insights using a more stringent TMA definition that we
believe more closely defines TMA in the setting of aHUS. When
TMA manifestations based only on changes in single laboratory
values were excluded, the rate off treatment was 15.6-fold higher
than on treatment. These results taken together could suggest
worse outcomes for patients who discontinue eculizumab, al-
though it is possible that changes in single laboratory values may
signal subclinical disease processes.
Patients with identified complement abnormalities had sta-
tistically significantly higher TMA rates than patients with no
identified abnormalities. CFH and CFI mutations were predomi-
nant among patients who experienced TMA, regardless of treat-
ment status. This finding is consistent with previous
Table 2. Demographic and baseline clinical characteristics in the parent studies
Characteristic
Ongoing eculizumab Discontinued Total
(n¼ 48) (n¼ 39) (n¼ 87)
Age at first-ever infusion of eculizumab, years
Median (range) 24.0 (0.0–65.0) 21.0 (0.0–80.0) 22.0 (0.0–80.0)
<12, n (%) 13 (27) 11 (28) 24 (28)
12 to <18, n (%) 6 (13) 5 (13) 11 (13)
18, n (%) 29 (60) 23 (59) 52 (60)
Age at entry to current study, years
Median (range) 27.5 (2.5–67.6) 25.1 (1.6–81.6) 26.0 (1.6–81.6)
<12, n (%) 10 (21) 11 (28) 21 (24)
12 to <18, n (%) 3 (6) 0 (0) 3 (3)
18, n (%) 35 (73) 28 (72) 63 (72)
Female, n (%) 30 (63) 23 (59) 53 (61)
Complement gene mutation or autoantibody, n (%) 31 (65) 20 (51) 51 (59)
CFHa 12 (25) 8 (21) 20 (23)
CFH autoantibodiesb 6 (13) 1 (3) 7 (8)
C3 6 (13) 1 (3) 7 (8)
CD46 (MCP) 2 (4) 5 (13) 7 (8)
CFI 3 (6) 4 (10) 7 (8)
C3, CFHR3-CFHR1 1 (2) 0 1 (1)
CD46 (MCP), CFI 1 (2) 0 1 (1)
CFB 0 1 (3) 1 (1)
Identified CFHR1, CFHR3 deletion 0 1 (3) 1 (1)
Time from last pretreatment aHUS manifestation to
first-ever dose of eculizumab, median (range), months
2.3 (0.0–47.4) 0.5 (0.0–19.2) 0.9 (0.0–47.4)
Family history of aHUS, n (%) 8 (17) 8 (21) 16 (18)
Time from aHUS diagnosis to first-ever dose of
eculizumab, median (range), months
18.4 (0.0–313.3) 0.9 (0.0–178.1) 4.0 (0.0–313.3)
History of TMA manifestations, n (%)
Single 29 (60) 27 (69) 56 (64)
Multiple 19 (40) 12 (31) 31 (36)
Prior renal transplant, n (%) 14 (29) 8 (21) 22 (25)
PE/PI sessions per patient, median (range) 13.3 (0.0–230.0) 7.0 (0.0–64.0) 11.0 (0.0–230.0)
Dialysis at baselinec, n (%) 14 (29) 15 (39) 29 (33)
eGFRd at baseline, median (range), mL/min/1.73 m2 21.2 (8.4–128.3) 12.1 (5.3–105.5) 18.9 (5.3–128.3)
aIncludes patients with additional abnormalities [i.e. C3, CD46 (MCP), CFI, CFHR1, CFHR3, and CFHR3-CFHR1].
bIncludes patients with additional abnormalities (i.e. CFHR1, CFHR3, CFHR3-CFHR1).
cDialysis at baseline was defined as any dialysis that occurred within 7 days prior to or 14 days following the first eculizumab dose in the parent study.
deGFR was defined as 10 mL/min/1.73 m2 when a patient was on dialysis.
PE/PI, plasma exchange/plasma infusion.
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observational studies of the natural history of aHUS [2, 3]. In a
small observational study, Ardissino et al. [28, 29] also noted
particular risk for TMA in patients who chose to discontinue
eculizumab with CFH mutations, and CFI mutations to a lesser
extent. In a retrospective study of eculizumab discontinuation
in a French cohort (n¼ 38) [27], all 12 patients (32%) with TMA
post-eculizumab discontinuation had rare or novel CFH or MCP
variants; both were independent risk factors for TMA following
discontinuation. However, patients with transplant, on
chronic dialysis or ‘secondary’ aHUS were excluded from the
French cohort. Results of the current analysis, which are from
the single largest prospective study of TMA risk following
eculizumab discontinuation, reinforce previous findings that
patients who discontinued eculizumab were at greater risk for
TMA compared with patients on treatment, and particularly
those with identified complement abnormalities. In this study,
patients without identified abnormalities were at a signifi-
cantly lower yet distinct risk for TMA after eculizumab discon-
tinuation. However, genetic analyses were performed during
the parent studies several years ago; thus, it is possible that
novel mutations not known at that time have been left
unrecognized.
Overall, characteristics of patients with TMA manifestations
were highly heterogeneous with respect to age, treatment
Table 4. Reported TMAmanifestations in patients on treatment with eculizumab
Patient demographics and clinical characteristics Eculizumab therapya
Patient Sex
Patient age
(years)
Complement
abnormality
Treatment
duration
(months)
Labelled
regimenb
TMA manifestation
based on single lab
criterion
Criteria achieved
for TMA
manifestation
SAE/
hospitalizationc
1 Female 4 None identified 26 No Yes "SCr No
2 Female 31 CFH 28 Yes Yes #Platelets Yes
3 Female 44 CFH 20 Yes Yes "LDH No
4 Female 12 CFH 59 Yes Yes "SCr No
5 Female 44 CFI 19d Yes Yes #Platelets Yes
6 Male 27 MCP 51 Yes Yes "LDH No
60 No Yes "LDH No
7 Male 49 CFI 39 Yes No Dialysis Yes
8 Female 10 CFH 56 No Yes "SCr No
61 No No "SCr, #platelets, No
"Proteinuria
9 Male 15 CFH 41 No Yes #Platelets No
44 No Yes "SCr No
53 No Yes "SCr No
10 Male 20 None identified 3 Yes Yes "LDH No
aDuring the current study only (i.e. excluding the parent study).
bNo TMA manifestations occurred while patients received dosing higher than approved by regulatory authorities.
cBefore or during TMA manifestation.
dThe patient’s first on-treatment period was 19 months, followed by an off-treatment period of 31 months and another on-treatment period of 10 months.
LDH, lactate dehydrogenase; SCr, serum creatinine.
Table 5. TMAmanifestation rates
Eculizumab treatment status Eculizumab dosing
Excluding single laboratory
change criterion
Parameter
Off
treatment
On
treatment
Non-labelled
regimen
Labelled
regimen
Off
treatment
On
treatment
(n¼ 39) (n¼ 76) (n¼ 33) (n¼ 65) (n¼ 39) (n¼76)
Patients with manifestation, n (%) 11 (28) 10 (13) 4 (12) 7 (11) 8 (21) 2 (3)
Total number of manifestations 14 14 7 7 11 2
Total patient-years 70.5 192.8 57.9 135.0 70.5 192.8
TMA manifestation rate/
100 patient-years
19.9 7.3 12.1 5.2 15.6 1.0
Fold change in ratea 2.7 Ref 2.3 Ref 15.6 Ref
Per cent change compared
with off treatmentb (%)
Ref 63 39 74 Ref 94
HR (P value)c 4.7 (P¼ 0.0008) Ref 1.3 (P¼ 0.7000)d Ref 16.8 (P¼ 0.0010) Ref
aOff treatment compared with on treatment (overall) or non-labelled compared with labelled regimen for the same analysis.
bOn treatment (overall), non-labelled or labelled regimen compared with off treatment for the same analysis.
cHRs were based on Cox proportional hazards model of time to first TMA manifestation, with treatment status as a time-dependent explanatory variable and comple-
ment abnormality status as a covariate.
dCompared with the labelled dosing regimen of eculizumab.
Ref, reference value.
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duration and duration of eculizumab before onset of TMA.
Age, frequency of complement abnormalities and kidney
transplant status did not differ between patients who discon-
tinued versus remained on eculizumab. However, patients
who discontinued appeared to have poorer renal function
at baseline in the parent study and initiated eculizumab more
rapidly. Such patients may have had clinically significant
renal improvement with eculizumab, since they initiated
treatment in a rapid manner [31], followed by the clinical deci-
sion to discontinue treatment after recovery. Discontinuation
of therapy was not randomized, potentially allowing selection
bias for continuing versus discontinuing eculizumab. In the
previously cited studies [26–28], not all patients with aHUS
were included. In the current study, all patients who met in-
clusion criteria for the parent studies (including those with di-
alysis and renal transplants) were allowed to enrol. Further
studies are needed to identify patient characteristics poten-
tially associated with increased risk for TMA after eculizumab
discontinuation.
Notably, 17/39 patients (44%) reinitiated eculizumab follow-
ing a period of discontinuation, including 9/11 patients (82%)
who had TMA manifestations while off treatment. After reini-
tiation, 14/17 patients (82%) continued eculizumab. Longer term
evaluation may provide additional insight as to clinical out-
comes associated with therapy stops and restarts.
Collectively, the current results reinforce the need for ongo-
ing treatment with eculizumab to minimize risk of TMA in
patients with aHUS, particularly those with an identified com-
plement abnormality. Although thorough genetic testing
informs prognosis, additional considerations when optimizing
treatment strategy include the patient’s unique clinical situa-
tion, age, TMA and family histories, as well as recognition of the
complex and unpredictable nature of aHUS. For individual
patients in whom discontinuation of eculizumab is being con-
sidered, clinicians would be well advised to consult an expert
centre in the field while ensuring that the patient: (i) has been
treated for a sufficiently long period to ensure maximal organ
function recovery; (ii) can be monitored closely for signs and/or
symptoms of TMA; and (iii) has immediate access to eculizumab
so treatment can be restarted at the first signs and/or symp-
toms of TMA [27, 32].
As was observed in the parent studies [7–10], eculizumab
was generally well tolerated in the current study. Rates of seri-
ous targeted TEAEs, including infections, reported off and on
treatment were similar. In particular, rates of renal impairment
were relatively high both off and on treatment, but commonly
associated with new kidney transplantation and existing graft
failure. Two patients reported meningococcal infections during
the current study. Both recovered and there were no changes
in eculizumab dosing. Frequency of meningococcal infections
[2/87 patients (2%)] is similar to that from the overall parent trial
programme of eculizumab in aHUS [two cases/100 total patients
(2%)] [7–10]. Overall, the reported meningococcal infection rate
in patients treated with eculizumab is 0.3 events/100 patient-
years [33]. Regulatory guidance for eculizumab includes in-
creased susceptibility to meningococcal infection [5, 6]. Patients
should be counselled in order to fully understand potential ben-
efits and risks of treatment, early signs of meningococcal dis-
ease and processes for seeking immediate medical care. Risks of
potentially severe complications, including meningococcal in-
fection, should be considered during the decision-making pro-
cess regarding initiating treatment or discontinuing
eculizumab. Long-term evaluations of the eculizumab safety
profile will be included in future analyses from the Global aHUS
Registry [34].
An important study limitation was its open-label and obser-
vational nature. Voluntary patient enrolment into this prospec-
tive study may have introduced selection bias because data are
not available for patients who completed a parent study but did
not consent to enrolment in the current study. In this analysis,
43/130 patients (33%) who enrolled in one of the parent studies
had not continued into the current study. During the parent and
current studies, which together included a median exposure of
45.9 months, withdrawal of eculizumab due to an AE was
uncommon. One adult patient died due to multiorgan failure
following a reduced dosing regimen. One paediatric patient dis-
continued eculizumab in the parent study due to agitation [9].
Three patients with previous renal transplants and poor renal
function (eGFR<30 mL/min/1.73 m2) at the start of treatment
discontinued eculizumab following reports of renal impairment
in the current study; of these, one later restarted eculizumab
and the other two received additional renal transplants.
Additional studies are needed to further understand patient
and physician rationale for discontinuing and reinitiating
treatment.
Taken together, findings from this interim analysis suggest
that patients with aHUS have an increased risk for TMA mani-
festations after discontinuation of eculizumab or during non-la-
belled regimens compared with labelled eculizumab dosing.
These results support current regulatory guidance [5, 6] in not-
ing potential risk for TMA following discontinuation of eculizu-
mab. Evidence demonstrates that patients had a 63–94% lower
risk of TMA on eculizumab therapy, depending on the definition
used. Future analyses will allow for further characterization of
TMA and evaluation of longer term outcomes on labelled or
non-labelled regimens of eculizumab and after therapy
discontinuation.
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